Roche to buy privately-held Kapa Biosystems to strengthen genetic research profile

19 August 2015
mergers-acquisitions-big

Swiss drug major Roche (ROG: SIX) on Wednesday said it has agreed to acquire privately-held Kapa Biosystems for an undisclosed sum in a bid to strengthen its genetic research portfolio.

The company in a statement said Kapa's protein-engineering technology allows for the generation and screening of large numbers of enzyme variants.

Roland Diggelmann, chief operating officer for Roche Diagnostics, said: “Kapa’s technology and products complement our current expertise and offerings such as the portfolio of target enrichment products for next-generation sequencing (NGS).”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical